**Supplemental Table 1. Cross-sectional areas of spinal cord (mean±SEM)**

 **Cross-Sectional Area (mm3)**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

 **RTS CTS AF TT Total**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Experiment 1 (Single BrdU injection)**

**1-Day Survival**

Transected 278,352 ± 22,661 278,256 ± 31,809 60,404 ± 6,644 37,892 ± 4,448 654,904 ±58,092

Sham 222,031 ± 22,301 271,118 ± 21,426 58,374 ± 3,075 33,805 ± 6,277 585,328 ± 36,439

**14-Day Survival**

Transected 311,378 ± 12,655 324,796 ± 22,705 67,368 ± 12,078 44,666 ± 7,391 748,208 ± 40,627

Sham 445,396 ± 59,105 329,473 ± 62,251 79,386 ± 8,072 59,296 ± 5,206 913,551 ± 125,632

**Experiment 2 (Five BrdU injections)**

**14-Day Survival\***

Transected 441,889 ± 35,350 355,296 ± 12,830 87,398 ± 4,248 45,741 ± 6,992 930,324 ± 43,137

Sham† 255,431 ± 31,397 196,835 ± 46,498 49,442 ± 3,033 25,363 ± 3,983 527,071 ± 76,134

Unoperated† 163,788 ± 6,378 145,742 ± 9,957 48,635 ± 4,448 29,395 ± 3,980 387,560 ± 15,627

**30-Day Survival\***

Transected 371,404 ± 17,126 365,483 ± 30,036 72,772 ± 7,458 37,568 ± 4,498 847,228 ± 37,574

Sham 356,251 ± 33,064 261,953 ± 50,615 48,389 ± 7,269 32,912 ± 5,493 699,515 ± 83,693

Unoperated† 229,296 ± 20,226 204,232 ± 13,621 50,380 ± 7,545 32,794 ± 5,660 516,702 ± 38,941

\* Significant effect of treatment (ANOVA, p<0.05); †Significantly less than Transected group (PLSD, p<0.05)